Palvella Therapeutics (NASDAQ:PVLA) Given “Buy” Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Palvella Therapeutics (NASDAQ:PVLA) in a research report released on Tuesday,Benzinga reports. They currently have a $38.00 price target on the stock.

PVLA has been the subject of several other reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $39.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Jones Trading started coverage on shares of Palvella Therapeutics in a report on Tuesday, March 25th. They set a “buy” rating and a $45.00 price objective for the company. Scotiabank assumed coverage on shares of Palvella Therapeutics in a research report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 price objective on the stock. TD Cowen assumed coverage on shares of Palvella Therapeutics in a research report on Wednesday, February 5th. They issued a “buy” rating and a $44.00 target price for the company. Finally, Stifel Nicolaus began coverage on Palvella Therapeutics in a report on Wednesday, March 26th. They set a “buy” rating and a $45.00 price target on the stock. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $43.50.

Palvella Therapeutics Trading Down 15.7 %

Palvella Therapeutics stock opened at $23.59 on Tuesday. Palvella Therapeutics has a 12 month low of $6.20 and a 12 month high of $29.27. The business has a fifty day simple moving average of $20.75. The company has a market cap of $264.70 million, a price-to-earnings ratio of -1.95 and a beta of 0.54.

Institutional Trading of Palvella Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. BML Capital Management LLC bought a new stake in shares of Palvella Therapeutics during the 4th quarter valued at $506,000. Geode Capital Management LLC bought a new stake in Palvella Therapeutics during the fourth quarter valued at about $171,000. ADAR1 Capital Management LLC purchased a new stake in Palvella Therapeutics in the fourth quarter worth about $1,736,000. Renaissance Technologies LLC bought a new position in shares of Palvella Therapeutics in the fourth quarter worth about $256,000. Finally, Blue Owl Capital Holdings LP bought a new position in shares of Palvella Therapeutics in the fourth quarter worth about $3,001,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

About Palvella Therapeutics

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.